What did the WARSS study find regarding warfarin and aspirin in patients with stroke not attributable to cardioembolism or high-grade carotid stenosis?
The WARSS study randomized 2206 patients with stroke not attributable to cardioembolism or high-grade carotid stenosis to adjusted-dose warfarin. The primary end point of 2-year recurrent ischemic stroke or death was no different between the 2 groups (17.8% warfarin versus 16% acetylsalicylic acid; HR, 1.13 [95% CI, 0.92 1.38]).